MASH is a serious form of liver disease characterized by excess fat buildup and inflammation. It can lead to liver scarring and in more severe cases, liver failure or cancer. The condition is often associated with other health problems, such as high blood pressure, Type 2 diabetes and obesity.The agency's approval is also a big deal because it means Madrigal has succeeded in an area where several other drugmakers haveacross the U.S., France, Germany, Italy, Spain, the U.K.
"The absence of liver biopsy requirement in Rezdiffra's label should buoy biotech stocks" of companies developing MASH treatments and"potentially accelerate and broaden patient access," William Blair analyst Andy Hsieh wrote in a note Friday.In this photo illustration, the Madrigal Pharmaceuticals logo is displayed on a smartphone screen.But the question for all of those companies is how much a blockbuster class of drugs called GLP-1s will dominate the MASH market.
We'll likely have a better idea of what the MASH drug landscape will look like over the next year – and how big a threat GLP-1s will be – so stay tuned for our coverage!Perhaps unsurprisingly, generative artificial intelligence dominated my conversations at the HIMSS conference in Orlando, Florida last week.and more, the topic was quite literally hard to avoid.